Suchergebnisse

Bluetongue serotype 8 has become a major animal health issue in the European Union and the Europeanmember States have agreed on a vaccination strategy, which involves only inactivated vaccines. Inthis study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used inEurope since 2008, BTVPUR ALSAP® 8 (MERIAL) and BOVILIS® BTV8 (Intervet/SP-AH), was evaluated ingoats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological,virological and clinical examinations were conducted before and after challenge. Three groups of 10 goatseach (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinatedtwice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8(group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulentinoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculumwas contaminated with another BTV serotype. However, results demonstrated that vaccination of goatswith two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection againsta BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative datashowed no difference in the kinetics and levels of the humoral response induced by these two inactivatedvaccines.